Located in Cranbury, New Jersey, United States of America, Amicus Therapeutics is a public biopharmaceutical firm founded in February 4, 2002. During its formation, different venture firms came together to form it. Radius Ventures, Canaan Partners and New Enterprise Associates are examples of these firms.
From 2004 to 2008, Amicus operated on a single site in New Jersey. It was in late 2008, that it expanded to San Diego. In 2009 Amicus Therapeutics went public and acquired the trading symbol FOLD. Later on the same year, Amicus ended a contract between them and Shire. This was mainly attributed that they faced financial setbacks. It was in 2010 that it acquired grants from various foundations. The Michael J. Fox Foundation was among the firm’s donators. These donations made Amicus Therapeutics get back to its feet and even acquired few other firms. For example, Callidus Biopharma acquired in 2013 and Scioderm which was acquired 2 years later.
There are three top people that are involved in running and conducting the affairs of Amicus Therapeutics. They include John Crowley, who is the Chief Executive Officer, William Baird, who is the Chief Financial Officer and Bradley Campbell. Bradley Campbell serves as the Chief Operations Officer. All of the three individuals are people of great skill and expertise in the pharmaceutical industry.
John Crowley, for example, is a man of great experience in the field of business and Medicine. Harvard Business School was one of the Universities he attended, where he graduated with an MBA degree in 1997. He took part in the foundation of Novazyme Pharmaceuticals and Orexigen Therapeutics before joining Amicus Therapeutics (GoogleFinance). The research conducted at Amicus Therapeutics is mainly based on rare and orphan diseases. The Amicus team is heavily driven by the desire to develop enzyme replacement therapies.
Ever since February 2014, Amicus Therapeutics has been doing research on the Fabry disease (https://www.glassdoor.com/Reviews/Amicus-Therapeutics-Reviews-E26068.htm). Recently the firm developed Galafold also known as Migasalat. This is a treatment for Fabry disease and is aimed at control endogenous mutant alpha-galactosidase. Fabry disease is characterized by patients having strokes, pain throughout the body, heart disease or even kidney failure. If not controlled, the disease may lead to death. Amicus Therapeutics also has the ambition of coming up with the cure of the Pompe Disease and the Epidermolysis Bullosa. Truly every single day the team at Amicus Therapeutics works tirelessly to help and give the best available care to their patients.